Also, TRPC5 was suggested as a key mediator for the central effects of the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and semaglutide [34,35], used for type II diabetes and weight loss [56,57]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.